Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

SHA:688513 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,327	1,348	1,116	1,170	1,023	921.48
Other Revenue	1.84	1.84	1.42	0.63	0.07	0.44
Revenue	1,329	1,350	1,117	1,171	1,023	921.92
Revenue Growth (YoY)	1.66%	20.82%	-4.56%	14.43%	10.96%	-2.67%
Cost of Revenue	359.51	345.23	226.94	199.11	146.32	107.68
Gross Profit	969.44	1,005	890.18	971.4	876.62	814.23
Selling, General & Admin	514.96	552.93	483.43	564.44	528.06	526.16
Research & Development	257.94	262.77	237.45	229.99	199.59	153.17
Other Operating Expenses	49.33	17.37	17.46	18.15	15.75	14.07
Operating Expenses	821.29	836.11	737.98	814	741.14	695.52
Operating Income	148.15	168.42	152.2	157.4	135.47	118.72
Interest Expense	-2.6	-3.68	-3.42	-2.61	-0.36	-0.72
Interest & Investment Income	23.7	27.38	25.61	20.69	32.83	13.26
Currency Exchange Gain (Loss)	0.16	0.16	0	0.03	0.02	-0.01
Other Non Operating Income (Expenses)	0.02	0.28	-0.1	-0.11	-0.19	0.1
EBT Excluding Unusual Items	169.43	192.56	174.29	175.41	167.77	131.35
Gain (Loss) on Sale of Investments	14.76	14.92	14.57	19.99	13.69	-
Gain (Loss) on Sale of Assets	-0.09	-0.11	0.03	0.19	-0.1	-0.01
Other Unusual Items	81.25	45.22	52.76	66.4	65.56	67.71
Pretax Income	263.31	252.59	241.64	261.99	246.92	199.05
Income Tax Expense	21.94	14.35	15.07	15.47	14.49	20.89
Net Income	241.37	238.23	226.57	246.52	232.43	178.16
Net Income to Common	241.37	238.23	226.57	246.52	232.43	178.16
Net Income Growth	-3.40%	5.15%	-8.09%	6.06%	30.46%	64.04%
Shares Outstanding (Basic)	176	175	177	177	176	147
Shares Outstanding (Diluted)	176	175	177	177	176	147
Shares Change (YoY)	-0.11%	-1.04%	0.14%	0.37%	19.70%	11.50%
EPS (Basic)	1.37	1.36	1.28	1.39	1.32	1.21
EPS (Diluted)	1.37	1.36	1.28	1.39	1.32	1.21
EPS Growth	-3.30%	6.25%	-8.22%	5.68%	8.98%	47.12%
Free Cash Flow	252.27	145.82	99.99	-187.38	-122.59	-42.28
Free Cash Flow Per Share	1.43	0.83	0.56	-1.06	-0.70	-0.29
Dividend Per Share	0.430	0.430	0.395	0.381	0.531	0.204
Dividend Growth	8.97%	8.97%	3.57%	-28.19%	159.97%	-
Gross Margin	72.95%	74.42%	79.68%	82.99%	85.70%	88.32%
Operating Margin	11.15%	12.48%	13.62%	13.45%	13.24%	12.88%
Profit Margin	18.16%	17.65%	20.28%	21.06%	22.72%	19.32%
Free Cash Flow Margin	18.98%	10.80%	8.95%	-16.01%	-11.98%	-4.59%
EBITDA	235.62	249.79	225.43	215.75	168.08	151.7
EBITDA Margin	17.73%	18.51%	20.18%	18.43%	16.43%	16.45%
D&A For EBITDA	87.48	81.37	73.23	58.35	32.6	32.98
EBIT	148.15	168.42	152.2	157.4	135.47	118.72
EBIT Margin	11.15%	12.48%	13.62%	13.45%	13.24%	12.88%
Effective Tax Rate	8.33%	5.68%	6.24%	5.90%	5.87%	10.49%
Revenue as Reported	1,329	1,350	1,117	1,171	1,023	921.92
Advertising Expenses	-	-	-	403	393.56	413.35

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.